PMID- 37049514
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230415
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 15
IP  - 7
DP  - 2023 Mar 30
TI  - Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in 
      Patients with Lymphocytic Colitis and Mood Disorders.
LID - 10.3390/nu15071674 [doi]
LID - 1674
AB  - Lymphocytic colitis (LC) is a gastrointestinal (GI) tract disease with poorly 
      known pathogenesis, but some environmental and lifestyle factors, including 
      certain dietary components, may play a role. Tryptophan is an essential amino 
      acid, which plays important structural and functional roles as a component of 
      many proteins. It is important in the development and maintenance of the body, in 
      which it is metabolized in two main pathways: kynurenine (KYN) and serotonin. In 
      this work, we explored the effect of reducing of TRP in the diet of patients with 
      LC with mood disorders. We enrolled 40 LC patients who had a normal diet, 40 LC 
      patients with the 8-week diet with TRP content reduced by 25% and 40 controls. 
      All LC patients received budesonide at 9 mg per day, and the severity of their GI 
      symptoms was evaluated by the Gastrointestinal Symptoms Rating Scale. Mood 
      disorders were evaluated by the Hamilton Anxiety Rating Scale (HAM-A) and the 
      Hamilton Depression Rating Scale (HAM-D). The concentration of TRP and its 
      metabolites, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), kynurenic 
      acid (KYNA) and quinolinic acid (QA), in urine were determined. Budesonide 
      improved the GI and mental states of LC patients, and the diet with reduced TRP 
      content further amended these symptoms. Dietary intervention decreased the 
      concentration of 5-HIAA by about 50% (3.4 vs. 6.3) and QA by about 45% (3.97 vs. 
      7.20). These changes were correlated with a significant improvement in the 
      profitable action of budesonide on gastrointestinal and mental health of LC 
      patients as they displayed significantly lower GSRS, HAM-A and HAM-B scores after 
      than before the intervention-10.5 vs. 32, 11.0 vs. 21 and 12 vs. 18, 
      respectively. In conclusion, a reduction in TRP intake in diet may improve GI and 
      mental symptoms in LC patients treated with budesonide and these changes may be 
      mediated by the products of TRP metabolism.
FAU - Chojnacki, Cezary
AU  - Chojnacki C
AUID- ORCID: 0000-0002-1620-4775
AD  - Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical 
      University of Lodz, 90-647 Lodz, Poland.
FAU - Gasiorowska, Anita
AU  - Gasiorowska A
AD  - Department of Gastroenterology, Medical University of Lodz, 92-213 Lodz, Poland.
FAU - Poplawski, Tomasz
AU  - Poplawski T
AUID- ORCID: 0000-0003-2300-7339
AD  - Department of Pharmaceutical Microbiology and Biochemistry, Medical University of 
      Lodz, 92-215 Lodz, Poland.
FAU - Blonska, Aleksandra
AU  - Blonska A
AD  - Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical 
      University of Lodz, 90-647 Lodz, Poland.
FAU - Konrad, Paulina
AU  - Konrad P
AD  - Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical 
      University of Lodz, 90-647 Lodz, Poland.
FAU - Zajdler, Radoslaw
AU  - Zajdler R
AD  - Department of Computer Science in Economics, University of Lodz, 90-237 Lodz, 
      Poland.
FAU - Chojnacki, Jan
AU  - Chojnacki J
AUID- ORCID: 0000-0001-8766-7868
AD  - Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical 
      University of Lodz, 90-647 Lodz, Poland.
FAU - Blasiak, Janusz
AU  - Blasiak J
AUID- ORCID: 0000-0001-9539-9584
AD  - Department of Molecular Genetics, University of Lodz, 90-236 Lodz, Poland.
LA  - eng
GR  - 503/6-006-05/503-61-001-19-00/Medical University of Lodz/
PT  - Journal Article
DEP - 20230330
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 8DUH1N11BX (Tryptophan)
RN  - 343-65-7 (Kynurenine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - 51333-22-3 (Budesonide)
SB  - IM
MH  - Humans
MH  - *Tryptophan/metabolism
MH  - Kynurenine/metabolism
MH  - Mood Disorders
MH  - Hydroxyindoleacetic Acid
MH  - Budesonide/therapeutic use
MH  - *Colitis, Lymphocytic
MH  - Diet
PMC - PMC10097278
OTO - NOTNLM
OT  - anxiety and depression
OT  - dietary intervention
OT  - food intake control
OT  - lymphocytic colitis
OT  - tryptophan
OT  - tryptophan metabolism
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:42
PMCR- 2023/03/30
CRDT- 2023/04/13 01:24
PHST- 2023/03/15 00:00 [received]
PHST- 2023/03/25 00:00 [revised]
PHST- 2023/03/29 00:00 [accepted]
PHST- 2023/04/14 06:42 [medline]
PHST- 2023/04/13 01:24 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/03/30 00:00 [pmc-release]
AID - nu15071674 [pii]
AID - nutrients-15-01674 [pii]
AID - 10.3390/nu15071674 [doi]
PST - epublish
SO  - Nutrients. 2023 Mar 30;15(7):1674. doi: 10.3390/nu15071674.